Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Lymphoid 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Solitary Pulmonary Nodule 1Smoking Cessation 1Multiple Pulmonary Nodules 1Mesothelioma 1Lymphoma, B-Cell 1Lung Neoplasms 1Cigarette Smoking 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 387Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × 4-(3-fluoropropyl)glutamic acid × Clear all
NCT03824535 2025-04-09

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

Stanford University

Phase 2 Completed
15 enrolled 7 charts

Smoking Cessation, Multiple Pulmonary Nodules

NCT02448225 2022-10-19

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
46 enrolled 12 charts
Thoracic

Cigarette Smoking, Solitary Pulmonary Nodule, Lung Neoplasms

NCT02599194 2019-01-03

18F-FSPG PET/CT for Cancer Patients on Therapy

Stanford University

Phase 2 Completed
7 enrolled 6 charts
BreastGenitourinaryLymphoidOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Lymphoma, B-Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡